98%
921
2 minutes
20
chronic lung infections pose serious challenges for phage therapy due to high between-patient strain diversity and rapid within-patient phenotypic and genetic diversification, necessitating simple predictors of efficacy to streamline phage cocktail design. We quantified bacteria-phage infection networks (BPINs) for six phages against 900 clones previously isolated from 10 bronchiectasis infections ( = 90 isolates per patient). BPIN structure varied extensively between patients. The efficacy of the six-phage cocktail against these diverse populations was influenced by several factors. Cocktail efficacy increased with decreasing number and strength of individual resistances, as well as with increasing co-resistance modularity and phage dose. These results highlight simple BPIN metrics that could help guide the design of effective phage therapeutics. Resistance against some but not all the phages increased with higher number defence systems per genome, resulting in lower efficacy of the six-phage cocktail, suggesting that strains with fewer defence systems are better candidates for phage therapy. Overall, our findings suggest that 'off the peg' phage therapeutics are unlikely to be broadly effective against chronic respiratory infections, but that the design of personalised phage cocktails could be guided using simple BPIN metrics, and that defence systems per genome provide a useful rule of thumb for identifying highly treatable infections.This article is part of the discussion meeting issue 'The ecology and evolution of bacterial immune systems'.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409361 | PMC |
http://dx.doi.org/10.1098/rstb.2024.0080 | DOI Listing |
Trends Microbiol
September 2025
Marine Biological Section, Department of Biology, University of Copenhagen, Helsingør, Denmark; HADAL & Nordcee, Department of Biology, University of Southern Denmark, Odense, Denmark. Electronic address:
As antimicrobial resistance threatens the future of the aquaculture industry, numerous studies have investigated the use of phages against aquaculture diseases over the past decades. Despite reports of efficient pathogen control, commercial phage solutions are sparse. We discuss limitations of phage therapy and provide suggestions for the progression towards commercially viable solutions.
View Article and Find Full Text PDFJ Control Release
September 2025
Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia; Materials Research Laboratory, University of California, Santa Barbara, CA 93106, USA. Electronic address:
Most chemotherapeutics distribute non-specifically throughout the body, resulting in off-target toxicities. Nanoparticle (NP) formulations provide a strategy to improve drug delivery by extending circulation time, protecting therapeutic agents from degradation, and enabling controlled release. However, delivering NPs effectively to solid tumors remains challenging due to the barriers within the tumor microenvironment.
View Article and Find Full Text PDFFood Res Int
November 2025
Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), 1068 Xueyuan Avenue, Shenzhen 518055, China. Electronic address:
Inflammatory bowel disease (IBD) encompasses two main conditions: Crohn's disease and ulcerative colitis. The role of foodborne pathogens, often transmitted through contaminated food, is a subject of ongoing research regarding their potential involvement in IBD. The most common foodborne pathogens S.
View Article and Find Full Text PDFInt J Antimicrob Agents
September 2025
Institute for Technology Assessment and Systems Analysis (ITAS), Karlsruhe Institute of Technology, P.O. Box 3640, 76021 Karlsruhe, Germany. Electronic address:
As antibiotic resistance of bacterial pathogens spreads, interest in bacteriophage (phage) therapy has soared again in many countries. Currently, there is no phage therapeutic with marketing approval and phage treatments are relegated to few patients, mostly under compassionate use schemes when approved drugs failed or are unavailable. Commercially manufactured and approved phage preparations could both expand the availability of therapeutic phages for existing, exemptional treatment schemes and result in more broadly usable phage therapeutics with marketing authorization.
View Article and Find Full Text PDFInt J Antimicrob Agents
September 2025
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Non-Traditional Antibacterial Therapy (ESGNTA); Phage Canada, Maple, Ontario, Canada; Unity Health Toronto,
With antimicrobial resistance as a worldwide public health concern, bacteriophage (phage) therapy (PT) may help treat bacterial infections. However, given its particularities compared with traditional small molecule drugs, there are variations in how it is regulated worldwide. Regulators are key players governing PT, yet their perspectives have been largely unexplored.
View Article and Find Full Text PDF